[Postmenopausal osteoporosis].
Due to its incidence and clinical consequences osteoporosis followed by vertebral, hip, and forearm fractures represents an outstanding problem of nowadays' health care. Because of its high mortality rate hip fractures are of special interest. The number of fractures caused by postmenopausal osteoporosis increases with age. Costs of examinations and treatment of women with postmenopausal osteoporosis and fractures are also increasing and represent a significant amount all over the world. Organization of Osteoporosis Centres in Hungary was founded in 1995 and has been since functioning, however, only the one-sixth of osteoporotic patients are treated. Several risk factors are known in the pathogenesis of osteoporosis, first of all the lack of sufficient calcium and vitamin D intake, age, genetic factors, and circumstances known to predispose falling. Estrogen deficiency is the most likely cause of postmenopausal osteoporosis. Osteodensitometry by DEXA is the most important method to evaluate osteoporosis, since decrease in bone mineral density strongly correlates with fracture incidence. Physical, radiologic, and laboratory examination are also required at the first visit and during follow-up. The quantity of bone can hardly be influenced after the 35th year of age, thus prevention of osteoporosis has special significance: appropriate calcium and vitamin D supplementation, weight-bearing sports and physical activity can prevent fractures. According to the results from studies fulfilling the criteria of evidence-based medicine, first choice treatment of osteoporosis involves hormone replacement therapy, bisphosphonates, the tissue specific tibolone, raloxifen and calcitonin. Calcium and vitamin D supplementation are always necessary to be added to any antiporotic treatment. Other combinations of different antiporotic drugs are useless and make the treatment more expensive. Other treatments like massage, physiotherapy, hip-protecting pants, etc. as well as rehabilitation have special clinical significance.
László
Adám
A
Fóvárosi Onkormányzat Bajcsy-Zsilinszky Kórháza, Szúlészeti-Nógyógyászati Osztály, Budapest.
D015502:Absorptiometry, Photon; D045930:Anabolic Agents / Q000008:administration & dosage; D002116:Calcitonin / Q000008:administration & dosage; D002136:Calcium, Dietary / Q000008:administration & dosage; D004164:Diphosphonates / Q000008:administration & dosage; D015914:Estrogen Replacement Therapy; D005260:Female; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007529:Isoflavones / Q000008:administration & dosage; D009043:Motor Activity; D009652:Norpregnenes / Q000008:administration & dosage; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000175:diagnosis / Q000191:economics / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D048789:Phytoestrogens; D028321:Plant Preparations / Q000008:administration & dosage; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage; D012307:Risk Factors; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage; D014807:Vitamin D / Q000008:administration & dosage; D016474:Weight-Bearing
D045930:Anabolic Agents; D002136:Calcium, Dietary; D004164:Diphosphonates; D007529:Isoflavones; D009652:Norpregnenes; D048789:Phytoestrogens; D028321:Plant Preparations; D020845:Selective Estrogen Receptor Modulators; D014807:Vitamin D; D020849:Raloxifene Hydrochloride; D002116:Calcitonin; C027385:tibolone